A Fabry Disease Gene Therapy Study

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

May 2, 2023

Study Completion Date

May 2, 2023

Conditions
Fabry DiseaseLysosomal Storage Diseases
Interventions
GENETIC

FLT190

Gene Therapy product.

Trial Locations (13)

10032

Columbia University, New York

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

22030

Lysosomal and Rare Disorders Research and Treatment Center, Fairfax

90027

Kaiser Permanente, Los Angeles

Unknown

Medical University of Vienna, Vienna

Charité - Universitätsmedizin Berlin, Berlin

UKEA University Hospital Hamburg, Hamburg

University of Würzburg, Würzburg

Universita Federico II di Napoli, Napoli

Haukeland University Hospital, Bergen

Royal Free Hospital, London

Salford Royal NHS Foundation Trust, Salford

T2E 7Z4

Metabolics and Genetics in Calgary (MAGIC Clinic), Calgary

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Spur Therapeutics

INDUSTRY

NCT04040049 - A Fabry Disease Gene Therapy Study | Biotech Hunter | Biotech Hunter